Our findings suggest that direct targeting of Siglec-F+ neutrophils with a depleting antibody or G-CSF signaling inhibitor other than a STAT3 inhibitor for blocking the development of Siglec-F+ neutrophils could be a potential therapeutic approach for emphysema. Here, STAT3 is linked to pulmonary emphysema.